首页> 美国卫生研究院文献>BMJ Case Reports >Case Report: Treatment of refractory rheumatoid pleural effusion with abatacept
【2h】

Case Report: Treatment of refractory rheumatoid pleural effusion with abatacept

机译:病例报告:阿巴西普治疗难治性类风湿性胸腔积液

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rheumatoid pleural effusion is generally responsive to corticosteroids, but refractory cases require consideration of second-line therapy. Here we report the case of a 61-year-old man with rheumatoid arthritis (RA) who developed a large right-sided pleural effusion and was successfully treated with abatacept. Thoracocentesis showed a sterile exudate and an elevated adenosine deaminase level. The methotrexate and etanercept used to treat the RA were withheld initially while he underwent a trial of prednisolone 40 mg/day for the pleural effusion. However, the effusion did not respond to this therapy. Thoracoscopic biopsy of the right pleura revealed fibrotic changes with lymphocyte infiltration mainly composed of CD4 T cells and B cells but no evidence of malignancy or infection. The patient was started on abatacept and resumed methotrexate. The treatment was effective in our case. Abatacept should be considered as a treatment option in patients with refractory rheumatoid pleural effusion.
机译:类风湿性胸腔积液通常对皮质类固醇有反应,但难治性病例需要考虑二线治疗。在这里,我们报告了一名类风湿性关节炎(RA)的61岁男子的病例,该男子发展为右侧大面积胸腔积液,并成功地接受abatacept治疗。胸腔穿刺术显示无菌渗出液和升高的腺苷脱氨酶水平。甲氨蝶呤和依那西普用于治疗类风湿性关节炎最初是在他接受泼尼松龙40毫克/天用于胸腔积液的试验时被停用的。但是,积液对该疗法没有反应。右胸膜的胸腔镜活检显示纤维化改变,淋巴细胞浸润主要由CD4 T细胞和B细胞组成,但无恶性或感染迹象。患者开始接受阿巴西普治疗,并恢复使用甲氨蝶呤。在我们的情况下治疗是有效的。对于难治性类风湿性胸腔积液患者,应将Abatacept视为治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号